Literature DB >> 8414016

The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.

W R Woodward1, C W Olanow, R M Beckner, R A Hauser, L L Gauger, J M Cedarbaum, J G Nutt.   

Abstract

We monitored the motor response and plasma and ventricular CSF (CSFv) concentrations of L-dopa during IV infusions of L-dopa in two patients with advanced Parkinson's disease. Concentrations of L-dopa in CSFv mirrored, but lagged behind, those in plasma. In the fasting state, the duration, but not the magnitude, of the motor response was greater with increasing plasma and CSFv levels of L-dopa. During IV infusions of L-dopa following oral administration of phenylalanine, a large neutral amino acid that shares a transport system into the brain with L-dopa, the duration of the motor response was markedly attenuated despite undiminished CSFv levels of L-dopa. These observations suggest that either L-dopa entry into CSFv and the brain are differentially affected by phenylalanine or that phenylalanine affects other steps in the motor response. These observations demonstrate that, except in the fasting state, L-dopa in CSFv is not a reliable predictor of motor response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414016     DOI: 10.1212/wnl.43.9.1704

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.

Authors:  N Ogawa; K Tanaka; M Asanuma
Journal:  Neurochem Res       Date:  2000-06       Impact factor: 3.996

Review 2.  Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.

Authors:  Luxi Wang; Nian Xiong; Jinsha Huang; Shiyi Guo; Ling Liu; Chao Han; Guoxin Zhang; Haiyang Jiang; Kai Ma; Yun Xia; Xiaoyun Xu; Jie Li; Jing Y Liu; Tao Wang
Journal:  Front Aging Neurosci       Date:  2017-06-28       Impact factor: 5.750

Review 3.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.